This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Duration of Infertility in Men May Affect ... A longer duration of infertility was associated with lower sperm ... (13 Dec 2018)
Cannabis-Based Compound May Reduce Seizures ... Interest has been growing in the use of cannabinoids—the active ... (13 Dec 2018)
Study Reveals Sleep Problems in Young Adult ... A study published in the Journal of Sleep Research indicates ... (13 Dec 2018)
Risk Factors for Falling Are Different in ... Different factors were associated with falling in men versus ... (10 Dec 2018)
Regular flu shots may save heart failure ... Getting an annual flu shot can save heart failure patients’ ... (12 Dec 2018)
Wednesday, 14 November 2018 07:45

Study Explores Timing of Muscle-Related Problems of Statin Use Featured

Rate this item
(0 votes)

Statins have been linked with muscle pain and other musculoskeletal adverse events (MAEs) in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.


For the study, cases in which statins (atorvastatin, rosuvastatin, simvastatin, lovastatin, fluvastatin, pitavastatin, and pravastatin) were prescribed were extracted from the US Food and Drug Administration Adverse Event Reporting System Data Files.

The onset timing of statin-induced musculoskeletal adverse events (MAEs) differed with each statin. For example, the onset of MAEs was significantly faster with high-intensity statins including atorvastatin and rosuvastatin than with simvastatin. Concomitant use of drugs—even those that may increase the risk of MAEs—did not cause changes in the onset timing of MAEs associated with statins.

“Passive surveillance of adverse events has played a major role in securing drug safety as a system to detect unknown adverse events. Data mining using Food and Drug Administration Adverse Event Reporting System, which is a large-scale database, will be an aid to enhance drug safety,” said senior author Dr. Daiuke Kobayashi, of Josai University, in Japan.



Source: Wiley
Full bibliographic information

Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs. Pharmacol Res Perspect. 2018;e00439. 

Read 125 times

Latest news

Highlights

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…